Compositions monovalent for cd40l binding and methods of use
Abstract
The invention relates to antibody polypeptides that monovalently bind CD4OL. Antibody polypeptides that are monovalent for binding of CD4OL can inhibit CD4OL activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC4OL. in one aspect, a monovalent anti-CD4OL antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC4OL, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD4OL antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD4OL interactions in an individual and methods of treating diseases or disorders involving CD40/DC4OL interactions, the methods involving administering a monovalent anti-CD4OL antibody polypeptide to the individual.
Claims
exact text as granted — not AI-modified1 . An isolated antibody single variable domain polypeptide comprising CDR1-3, wherein said isolated antibody single variable domain specifically binds CD40L.
Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.